This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Neil Bander, MD
Professor of Urology at Cornell UNIV Medical College


Dr. Neil H. Bander is the Bernard and Josephine Chaus Professor in Urological Oncology and Director of Urological Oncology Research at Weill Cornell Medicine (WCM). His team at WCM has the world’s largest experience in antibody discovery and clinical development in urological cancers. His group developed the first monoclonal antibodies to prostate-specific membrane antigen (PSMA) that could successfully target prostate cancers in patients. This enabled them to define much of the biology of PSMA and clinically validate PSMA as a target in prostate and other cancers. As a result of Dr. Bander and his team’s pioneering efforts, PSMA has become a target of substantial interest and activity in bio-pharma leading to recent FDA approval of PSMA PET imaging and radioligand therapy.  

Dr. Bander is a surgeon-scientist trained in urological oncology and tumor immunology, both at Memorial Sloan-Kettering Cancer Center. He has authored approximately 200 peer-reviewed publications, and he is an inventor on approximately 150 US and foreign, issued and pending patents. He has served on, and chaired, multiple study sections and grant review panels and received several honors including the FC Valentine Fellowship from the NY Academy of Medicine, the Society of Surgical Oncology James Ewing Research Award, awards from the German and Japanese Urology Societies, the Prostate Cancer Foundation, and the Clark Medal for Surgical Innovation from the Royal College of Surgeons (London). He also serves on several industry Scientific Advisory Boards.

Agenda Sessions

  • Tumor-targeted Antibody-enzyme Fusions Direct Allo- or Xeno-antigen Biosynthesis to Trigger Hyper-acute Rejection